Skip to main content
SpringerLink
Log in

Comparison of the Efficacy and Safety of Low Molecular Weight Heparins and Unfractionated Heparin in the Initial Treatment of Deep Venous Thrombosis

An Updated Meta-Analysis

  • Published:
Drugs Aims and scope Submit manuscript

Summary

The aim of this study was to determine whether treatment with low molecular weight heparin (LMWH) reduces the incidence of recurrent thromboembolic events, death, haemorrhages, and extension of thrombus more than treatment with unfractionated heparin (UFH) in patients with established deep vein thrombosis (DVT).

The study design was an updated meta-analysis of results from 20 randomised controlled clinical studies comparing LMWH with UFH.

The main outcomes measured included i) the incidence of thromboembolic events (DVT and/or pulmonary embolism); ii) the incidence of major haemorrhages; iii) total mortality; and iv) extension of thrombus.

Statistically significant reductions in favour of LMWH were observed for mortality [common odds ratio (OR) 0.70, 95% confidence interval (CI) 0.50 to 0.98; p = 0.035], major haemorrhage (common OR 0.59, 95% CI 0.35 to 0.98; p = 0.042) and thrombus extension (common OR 0.65, 95% CI 0.44 to 0.96; p = 0.03). A nonsignificant trend, also in favour of LMWH, was observed for the recurrence of venous thromboembolic events (common OR 0.77, 95% CI 0.55 to 1.08; p = 0.13).

The results from the meta-analysis showed that LMWHs seem to have a higher benefit/risk ratio than UFH in the treatment of venous thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1: 1309–12

    Article  PubMed  CAS  Google Scholar 

  2. Brandjes DPM, Heijboer H, Biiller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485–9

    Article  PubMed  CAS  Google Scholar 

  3. Leizorovicz A, Simmoneau G, Decousus H, et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299–304

    Article  PubMed  CAS  Google Scholar 

  4. Cochran WG. Some methods of strengthening the common X2 tests. Biometrics 1954; 10: 417–51

    Article  Google Scholar 

  5. Fleiss J. Statistical methods for rates and proportions. New York: Wiley, 1973

    Google Scholar 

  6. Bratt G, Tornebohm E, Granqvist S, et al. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813–7

    PubMed  CAS  Google Scholar 

  7. Holm HA, Handeland GF, Abildgaard U, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 Suppl. 2: 30–7

    PubMed  Google Scholar 

  8. Faivre R, Neuhart Y, Kieffer Y, et al. Un nouveau traitement des thromboses veineuses profondes: les fractions d’héparine des bas poids moléculaire. Étude randomisée. Presse Med 1988; 17: 197–200

    PubMed  CAS  Google Scholar 

  9. Zanghi M, Morici V, Costanzo M, et al. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. J Int Med Res 1988; 16: 474–84

    PubMed  CAS  Google Scholar 

  10. Notarbartolo A, Salanitri G, Davi G, et al. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Praxis 1988; 9: 1–13

    Google Scholar 

  11. Étude Multicentrique Française. Traitement des thromboses veineuses profondes consitituées. Étude comparative d’unfragment d’héparine de bas poids moléculaire (Fragmine®) administrée par voie sous-cutanée et de l’héparine standard administrée par voie intraveineuse continue. Rev Med Interne 1989; 10: 375–81

    Article  Google Scholar 

  12. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989; 80: 935–40

    Article  PubMed  CAS  Google Scholar 

  13. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low molecular-weight heparin in acute venous thrombosis. Haemostasis 1990; 20 Suppl. 1: 205–19

    PubMed  Google Scholar 

  14. Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506–10

    PubMed  CAS  Google Scholar 

  15. A Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251–6

    Google Scholar 

  16. Prandoni P, Lensing AWA, Biiller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441–5

    Article  PubMed  CAS  Google Scholar 

  17. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14–8

    PubMed  CAS  Google Scholar 

  18. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975–82

    Article  PubMed  CAS  Google Scholar 

  19. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. A multicenter randomized trial: DVTENOX Study. Arch Intern Med 1993; 153: 1541–6

    Article  PubMed  CAS  Google Scholar 

  20. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clin Trials Meta-Anal 1993; 28: 215–25

    Google Scholar 

  21. Lindmarker P, Holmström M, Granqvist S, et al. Fragmin once daily subcutaneously in a fixed-dose compared with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis [abstract]. Thromb Haemost 1993; 69: 648

    Google Scholar 

  22. Luomanmäki K, Hallert C, Kim H. Low molecular weight heparin (Fragmin®) once daily vs continuous infusion of standard heparin in the treatment of DVT [abstract]. Haemostasis 1994 May; 24 Suppl. 1: 248.

    Google Scholar 

  23. Fiessinger JN, Lopez Fernandez M, Gatterer E, et al. Fragmin® once daily versus continuous infusion heparin in the treatment of DVT — an European multicentre trial [abstract]. Haemostasis 1994 May; 24 Suppl. 1: 44

    Google Scholar 

  24. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81

    Article  PubMed  CAS  Google Scholar 

  25. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682–7

    Article  PubMed  CAS  Google Scholar 

  26. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Department, Hôpital Neuro-Cardiologique, Bôite Postale 3041, 69394, Lyon Cedex 03, France

    A. Leizorovicz

Authors
  1. A. Leizorovicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leizorovicz, A. Comparison of the Efficacy and Safety of Low Molecular Weight Heparins and Unfractionated Heparin in the Initial Treatment of Deep Venous Thrombosis. Drugs 52 (Suppl 7), 30–37 (1996). https://doi.org/10.2165/00003495-199600527-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199600527-00006

Keywords

Search

Navigation